

Supplemental Table S2

Incidence of anti-drug antibodies by treatment (mITT population)

	PF-05280586 <i>n</i> = 73	Rituximab-EU <i>n</i> = 74	Rituximab-US <i>n</i> = 73
Samples tested, <i>n</i>			
Baseline	73	74	73
Post-dose	357	364	348
Patients with pre-existing ADA,* <i>n</i>			
Positive at baseline only	4	3	1
Positive at baseline and ≥ 1 sample post-dose	0	3	2
Patients with treatment-emergent ADA			
≥ 1 positive sample post-dose, <i>n</i>	7	10	9
Percentage of patients in the group, %	9.6	13.5	12.3

* Patients with pre-existing ADA had a baseline sample that tested positive for ADA mITT, modified intent-to-treat; ADA, anti-drug antibodies.